{"nctId":"NCT00490919","briefTitle":"Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain","startDateStruct":{"date":"2007-06"},"conditions":["Low Back Pain"],"count":539,"armGroups":[{"label":"Double-blind BTDS 10 or 20","type":"EXPERIMENTAL","interventionNames":["Drug: Buprenorphine transdermal system"]},{"label":"Double-blind Placebo TDS","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Buprenorphine transdermal system","otherNames":["Butransâ„¢"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with moderate to severe chronic low back pain (lasting several hours daily) as their predominant pain condition for at least 3 months prior to screening,\n* Subjects treated within the 14 days prior to screening with nonopioid therapy only, or with therapy including opioids at a dose of \\<5 mg oxycodone (or equivalent) per day,\n* Subjects whose low back pain is not adequately controlled with non-opioid analgesic medication and who the Investigator feels are appropriate candidates for around-the-clock opioid therapy\n\nExclusion Criteria:\n\n* Subjects who had a surgical procedure directed towards the source of back pain within 6 months of screening or planned during the study conduct period,\n* Subjects who are allergic to buprenorphine or who had a history of allergies to other opioids,\n* Subjects who have allergies or other contraindications to transdermal delivery systems or patch adhesives.\n\nOther protocol-specific inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average Pain Over the Last 24 Hours Scores at Week 12 of the Double-blind Phase.","description":"Pain was assessed on an 11-point numerical scale ranging from 0 = no pain to 10 = pain as bad as you can imagine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.24","spread":"1.263"},{"groupId":"OG001","value":"7.17","spread":"1.223"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.57","spread":"1.283"},{"groupId":"OG001","value":"2.56","spread":"1.207"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.83","spread":"2.738"},{"groupId":"OG001","value":"4.38","spread":"2.690"}]}]}]},{"type":"SECONDARY","title":"The Mean Daily Number of Tablets of Nonopioid Supplemental Analgesic Medications Taken During Weeks 2 Through 12 of the Double-blind Phase","description":"Nonopioid supplemental analgesic tablets were sponsor-supplied acetaminophen or ibuprofen.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.620","spread":"0.0658"},{"groupId":"OG001","value":"0.743","spread":"0.0574"}]}]}]},{"type":"SECONDARY","title":"The Sleep Disturbance Subscale in the Medical Outcome Study (MOS) Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase","description":"The MOS Sleep Scale consists of 12 individual items (4 sleep disturbance, 2 sleep adequacy, 1 quantity of and optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 and Questions 2 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.84","spread":"25.552"},{"groupId":"OG001","value":"41.20","spread":"26.813"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.63","spread":"26.276"},{"groupId":"OG001","value":"39.87","spread":"26.362"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.97","spread":"26.871"},{"groupId":"OG001","value":"40.42","spread":"26.675"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":256},"commonTop":["Nausea","Headache","Application site pruritus","Dizziness","Somnolence"]}}}